GRPR

By Targets:	Bombesin Receptor (11) Cholecystokinin Receptor (1) Mixed Lineage Kinase (1) NF-κB (1) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (1) RIP kinase (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116216

PD 168368	Bombesin Receptor	Cancer
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the K_i of 15–45 nM . PD 168368 is neuromedin B receptor (NMBR; IC₅₀=96 nM) / gastrin-releasing peptide receptor (GRPR IC₅₀=3500 nM) antagonist . PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC₅₀s of 0.57, 0.24, and 2.7 nM, respectively .

HY-115974

GRPR antagonist-1	Bombesin Receptor	Cancer
GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC₅₀ of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis, with anticancer activity .

HY-115975

GRPR antagonist-2	Bombesin Receptor	Cancer
GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC₅₀ of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity .

HY-RS05847

GRPR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GRPR Human Pre-designed siRNA Set A contains three designed siRNAs for GRPR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GRPR Human Pre-designed siRNA Set A GRPR Human Pre-designed siRNA Set A

HY-RS17163

Grpr Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Grpr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Grpr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Grpr Mouse Pre-designed siRNA Set A Grpr Mouse Pre-designed siRNA Set A

HY-RS23613

Grpr Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Grpr Rat Pre-designed siRNA Set A contains three designed siRNAs for Grpr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Grpr Rat Pre-designed siRNA Set A Grpr Rat Pre-designed siRNA Set A

HY-168633

*PSMA/GRPR* ligand 1**	Bombesin Receptor PSMA	Cancer
PSMA/GRPR ligand 1 (compound 3 ) is a bispecific *PSMA/GRPR* ligand that shows dual targeting for PSMA(+) and GRPR(+) tumors .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-W343750

[Tyr4]-Bombesin	Bombesin Receptor	Metabolic Disease
[Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .

HY-P0107

RC-3095	Bombesin Receptor	Inflammation/Immunology
RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P0107A

RC-3095 TFA 1 Publications Verification	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable *GRPR* selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the bombesin (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the bombesin (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

Cat. No.	Product Name	Target	Research Area